Canada Markets closed

Twitter, Inc. (TWTR)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
34.82-2.46 (-6.60%)
At close: 04:02PM EST
34.64 -0.18 (-0.52%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close37.28
Open36.90
Bid34.48 x 2200
Ask34.49 x 1000
Day's Range34.79 - 37.08
52 Week Range34.79 - 80.75
Volume25,562,415
Avg. Volume18,083,866
Market Cap27.842B
Beta (5Y Monthly)0.71
PE Ratio (TTM)N/A
EPS (TTM)-0.23
Earnings DateFeb. 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.19
  • Bloomberg

    Nobelist Stiglitz Rebuffed After Praising Argentina’s ‘Miracle’ Economy

    (Bloomberg) -- Nobel laureate economist Joseph Stiglitz is facing a wave of criticism from peers after he claimed crisis-prone Argentina is witnessing “an economic miracle.”Most Read from BloombergCrypto Crash Erases More Than $1 Trillion in Market Value‘Lethal’ U.S. Military Aid Begins Arriving in UkraineBitcoin Has Lost Half Its Value Since Hitting Record HighBitcoin Chart Hints at Possible Floor for SlideNasdaq 100’s Unrelenting Declines Ring a Dot-Com Bust Alarm BellStiglitz penned a Project

  • Reuters

    Twitter says two security team leaders leaving company

    The shakeup comes after Twitter co-founder Jack Dorsey stepped down as chief executive in November, handing the reins to top deputy Parag Agrawal, who has since reorganized the leadership structure of the social media company. Twitter did not specify whether the departures were voluntary. Peiter Zatko, a famed hacker more widely known as "Mudge," was appointed head of security in 2020 after Twitter suffered a security breach that allowed hackers to tweet from verified accounts for public figures including billionaire Bill Gates and Tesla CEO Elon Musk.

  • Motley Fool

    2 Growth Stocks That Could Take Off in February

    Novavax has been both a promising and frustrating stock to own recently. It's promising in the sense that its COVID-19 vaccine candidate could give the company a slice of what's proving to be a very large pie. The frustrating part about Novavax is that it has continually pushed back its schedule for applying to the U.S. Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA).